CTIS2022-502793-17-00进行中（未招募）1 期
An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE) - AA-HPP-407
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Participants must be = 2 years of age and < 18 years with open epiphyseal growth plates at the time of signing the informed assent/consent by the participant or their legal guardian., Reoccurrence or worsening of rickets for at least the past 3 months in participants who showed an initial efficacy response to asfotase alfa after at least 6 months of continuous treatment and currently receiving asfotase alfa. RSS will be used to determine severity at Baseline., Presence of ADAs, with or without NAbs, irrespective of their titers, Confirmation by the Treatment Monitoring Board (TMB) that both the clinical evidence and immunogenicity-mediated association noted above are present., Male or female, Female participants of childbearing potential and male participants with partners of childbearing potential must follow protocol-specified contraception guidance, Participant, or participant’s legal guardian, is capable of signing informed consent or assent, which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol.
排除标准
- •Non-immune-mediated LoE. Potential causes of non-immune-mediated LoE could include poor treatment adherence, inappropriate injection technique, vitamin D deficiency (vitamin D level should be > 20 ng/mL. If < 20 ng/mL at Screening, rescreening is allowed after vitamin D supplementation), undernutrition, or concomitant diseases, and should be ruled out when assessing participants for a suspected LoE of asfotase alfa., Female participants who have a positive pregnancy test at Screening or Day 1., Inability of the participant, or the participant’s legal guardian, to provide informed consent, Pregnant, breastfeeding, or intending to conceive during the course of the study., Inability to travel to the clinic for specified visits during the Treatment Period caused by disease per se or logistics (does not apply to external travel restrictions)., The participant is at risk of reactivation or has an active significant viral infection such as hepatitis B, cytomegalovirus, herpes simplex, human polyomavirus (also known as John Cunningham [JC] virus), parvovirus, or Epstein Barr virus., The participant is at risk of reactivation of tuberculosis or has regular contact (eg, in the household) with individuals who are being actively treated for tuberculosis., The participant has had or is required to have any live vaccination within 1 month prior to enrollment., Any medical condition (eg, cardiac, pulmonary, renal, hepatic, hematologic, oncologic,or psychiatric) that, in the opinion of the Investigator, might interfere with participation in the study (such as any interference with rituximab, methotrexate, and bortezomib), pose any added risk to the participant, or confound the assessment of the participant., Known history of human immunodeficiency virus (HIV) infection (evidenced by HIV type 1 or type 2 [HIV 1, HIV 2] antibody) or hepatitis B or C viral infection., History of hypersensitivity to any ingredient contained in any of the study interventions., Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to Screening., Evidence of severe hepatic or renal impairment or any other medical conditions that are contraindications for use of any of the components of the IST regimens according to the Reference Safety Information (RSI) or local approved product labeling., History of malignancy within 5 years of Screening that has been treated with no evidence of recurrence., Any concomitant medications contraindicated for rituximab, methotrexate, and bortezomib (including, but not limited to, those listed in the RSI for each IST)., Participation in another investigational drug or investigational device study within 30 days before the first dose administered in this study. Participants currently enrolled in the HPP Global Registry and/or HPP Registry Substudy should be discontinued prior to the Baseline of this study
研究者
相似试验
尚未招募
不适用
Intramuscular Ketamine use as an Antisuicidal drugCTRI/2022/09/045713I
尚未招募
2 期
Panchakarma procedures in the management of Rheumatoid arthritisCTRI/2021/09/036891Reetika Rana MD Student
尚未招募
Unknown
Effect of Medha Sukta Mantra on Cognition in Different Deha Prakriti IndividualsCTRI/2024/05/067259Parul Institute of Ayurved
招募中
不适用
An Investigator initiated study comparing of two antifungals Anidulafungin and Caspofungin in patients with Invasive Candida InfectionsCTRI/2021/09/037013Dr Yatin Mehta
尚未招募
不适用
An observational study between two drugs that prevent activity of the immune system in patients after liver transplantCTRI/2013/08/003938Medanta The Medicity50